OliX Pharmaceuticals to Present New Data in Liver and Ophthalmic Areas at 16th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS)


SUWON, Republic of Korea, Sept. 29, 2020 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, presents two virtual posters of their on-going clinical research at the 16th Annual Meeting of the Oligonucleotide Therapeutics Society on September 27 – 30. The presentations will focus on the results of the Company’s proprietary asymmetric siRNA (asiRNA) study, which confirms the therapeutic effects of RNAi-based therapeutics in patients with hepatic diseases and age-related macular degeneration.

Read the original post:
OliX Pharmaceuticals to Present New Data in Liver and Ophthalmic Areas at 16th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS)

Related Posts